HC Wainwright & Co. Reiterates Buy on Zentalis Pharma, Maintains $55 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Zentalis Pharma (NASDAQ:ZNTL) and maintained a $55 price target.
May 26, 2023 | 10:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Zentalis Pharma (NASDAQ:ZNTL) and maintained a $55 price target.
The reiteration of a Buy rating and maintenance of a $55 price target by HC Wainwright & Co. analyst Andrew Fein indicates a positive outlook for Zentalis Pharma. This news is likely to have a positive short-term impact on the stock price, as it shows confidence in the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100